At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 221–230 of 563 results.
-
Researchers in this study want to compare sentinel lymph node biopsy surgery with standard neck dissection as part of the treatment for people with early-stage oral cavity (mouth) cancer. Sentinel lymph node biopsy is a procedure that removes a smaller number of lymph nodes from the neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard elective neck dissection removes many of the lymph nodes in the neck but may reduce shoulder mobility and strength.
-
Researchers want to learn if combining lasofoxifene and abemaciclib works well in people with advanced breast cancer. This treatment will be compared to the usual breast cancer treatment with fulvestrant and abemaciclib. The people in this study have breast cancer that is fueled by estrogen and does not have the HER2 protein. They also have a mutation (change or variant) in the ESR1 gene. Lasofoxifene targets the ESR1 gene mutation.
-
The purpose of this study is to assess the safety of the investigational treatment REGN4018 alone and in combination with cemiplimab in women with ovarian, peritoneal, or fallopian tube cancer that has come back or gotten worse after previous treatment. REGN4018 is a type of drug called a bispecific antibody: it binds to two specific proteins (MUC16 and CD3) that may be involved in the growth and survival of cancer.
-
The purpose of this study is to find the highest dose of the investigational drug LOXO-435 that can be given safely in people with advanced solid tumors that have come back or continued to grow despite treatment and contain a change in the FGFR3 gene. LOXO-435 targets cells with this abnormality and blocks the activity of FGFR3, a protein that plays a role in cancer growth. Inhibiting this protein could slow or stop the growth of cancer. LOXO-435 is taken orally (by mouth).
- A Study of ST-01156 in People With Solid Tumor Cancer
Full Title A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients with Advanced Solid Malignancies
Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Robert Maki’s office at 646-888-5059.
Protocol
26-002Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07197554ClinicalTrials.gov
-
Myelofibrosis is a rare disease known as a myeloproliferative neoplasm. The bone marrow becomes scarred and cannot make enough blood cells, leading to anemia. Anemia is low number of red blood cells, causing tiredness and shortness of breath. Some people with myelofibrosis need regular transfusions of blood. In this study, researchers want to see if momelotinib given with luspatercept reduces the need for blood transfusions in these patients. Momelotinib works by blocking two proteins called JAK and ACVR1. When JAK proteins send too many signals, the body makes the wrong amount of blood cells. By blocking JAK, momelotinib may help your body make the right amount of blood cells. By targeting ACVR1, momelotinib may fight anemia. Momelotinib is taken orally (by mouth).  By improving red blood cell development, luspatercept may reduce the need for blood transfusions in people with transfusion-dependent myelofibrosis. Luspatercept is given by an injection under the skin. 
-
Researchers are doing this study to learn if lung chemoembolization is safe and works well in people with lung cancer. The people in this study have non-small cell lung cancer that keeps growing after chemotherapy. Moreover, it cannot be cured with surgery or radiation therapy.
-
I-DXd is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called B7-H3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, I-DXd may help slow or stop the growth of your cancer.
-
Casdozokitug blocks an immune system protein called IL-27. By binding to and blocking IL-27, casdozokitug may help immune cells fight cancer. Toripalimab also helps the immune system fight cancer. Bevacizumab prevents the growth of new blood vessels that feed the cancer. All three drugs are given intravenously (by vein).
-
Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene.